Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
JNJ-2056 by Johnson & Johnson Innovative Medicine for Tauopathies: Likelihood of Approval
JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Tauopathies. According to...
Data Insights
JNJ-2056 by Johnson & Johnson Innovative Medicine for Alzheimer's Disease: Likelihood of Approval
JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Alzheimer's Disease. According...